KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to 35.89%.

  • Esperion Therapeutics' EBITDA Margin rose 212900.0% to 35.89% in Q3 2025 from the same period last year, while for Sep 2025 it was 34.84%, marking a year-over-year decrease of 54700.0%. This contributed to the annual value of 15.57% for FY2024, which is 1643000.0% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' EBITDA Margin is 35.89%, which was up 212900.0% from 15.45% recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' EBITDA Margin peaked at 44.3% during Q1 2024, and registered a low of 1139.82% during Q1 2021.
  • For the 5-year period, Esperion Therapeutics' EBITDA Margin averaged around 230.25%, with its median value being 174.71% (2023).
  • As far as peak fluctuations go, Esperion Therapeutics' EBITDA Margin surged by 31136000bps in 2021, and later crashed by -2448000bps in 2022.
  • Esperion Therapeutics' EBITDA Margin (Quarter) stood at 423.02% in 2021, then surged by 30bps to 294.38% in 2022, then surged by 41bps to 174.71% in 2023, then surged by 82bps to 30.85% in 2024, then decreased by -16bps to 35.89% in 2025.
  • Its EBITDA Margin stands at 35.89% for Q3 2025, versus 15.45% for Q2 2025 and 62.24% for Q1 2025.